RAPP Reports $0 Revenue, $0 EPS, +0% YoY; Announces RAP-219 Phase 2a Follow-up Data Showing 90% Median Seizure Reduction, 22-Day Half-Life, Well-Tolerated
Rapport Therapeutics, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $37.11
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS